Athenex (NASDAQ:ATNX) and G1 Therapeutics (NASDAQ:GTHX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.
Valuation and Earnings
This table compares Athenex and G1 Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Athenex||$38.04 million||23.22||-$131.17 million||($2.32)||-5.70|
|G1 Therapeutics||$520,000.00||2,648.88||-$60.12 million||($3.57)||-11.55|
G1 Therapeutics has lower revenue, but higher earnings than Athenex. G1 Therapeutics is trading at a lower price-to-earnings ratio than Athenex, indicating that it is currently the more affordable of the two stocks.
This table compares Athenex and G1 Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
19.7% of Athenex shares are owned by institutional investors. Comparatively, 69.2% of G1 Therapeutics shares are owned by institutional investors. 29.5% of Athenex shares are owned by insiders. Comparatively, 15.9% of G1 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a summary of recent recommendations for Athenex and G1 Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Athenex presently has a consensus price target of $24.33, indicating a potential upside of 84.06%. G1 Therapeutics has a consensus price target of $74.50, indicating a potential upside of 80.65%. Given Athenex’s higher probable upside, equities analysts clearly believe Athenex is more favorable than G1 Therapeutics.
Risk and Volatility
Athenex has a beta of -1.66, indicating that its stock price is 266% less volatile than the S&P 500. Comparatively, G1 Therapeutics has a beta of -1.02, indicating that its stock price is 202% less volatile than the S&P 500.
G1 Therapeutics beats Athenex on 9 of the 14 factors compared between the two stocks.
Athenex Company Profile
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom. In addition, the company offers Src Kinase product candidates comprising KX-01, a compound, which is in Phase 3 study for the treatment of actinic keratosis; and KX-02 that is Phase I clinical trial for solid tumor patients. Further, it is developing intranasal formulations of granisetron, a 5-hydroxytryptamine 3 receptor antagonist to prevent chemotherapy-induced nausea and vomiting; and dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. has a strategic partnership with Hanmi Pharmaceuticals to develop their Orascovery and KX-01 programs. The company was founded in 2003 and is headquartered in Buffalo, New York.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.